Amarin Corp Plc (AMRN)

[jessellivermore]

raf... Thanks for posting...

Triple negative breast cancer (TNBC) is a particularly deadly form of breast cancer occurring in 12-20 % of women who have the disease...

Currently there is no effective treatment for this type of cancer which metastasizes early and is fatal in most cases...

Studies in mice where TNCB was grafted shows very promising results when EPA (actually Vascepa) was combined with agents that blocked Ephrin-type A receptor 2''(EPHA-2)....Increased EPHA-2 activity is associated with shorter survival in breast cancer...

EPA as we know lowers SI by competitively inhibiting pro inflammatory eicosanoid production from COX and LOX cell membrane receptors...These pro inflmmatory eicosanoids can promote the growth of cancers..The problem in TNBC is production of pro inflammatory prostiglandins from COX 2 receptors..

Blocking EPHA-2 receptors and adding Vascepa in mice that received transplants of this cancer (TBNC) showed that blocking the EPHA-2 receptors and adding EPA slowed the growth of the tumor down considerably by increasing apoptosis (cellular suicide).. in the grafts..We know EPA blocks pro inflammatory eicosanoids in COX 2 receptors..

Perhaps another promising indication for Vascepa...This should draw the attention of cancer scientist looking for answers in untreatable cancers...

A good thing for Amarin...

":>) JL